At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
saracatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD0530 in Patients With Metastatic or Locally Advanced Gastric Carcinoma
In Brief
A Phase 2 clinical trial evaluating saracatinib for Adenocarcinoma of the Gastroesophageal Junction and 6 related conditions. Completed, enrolled 21 participants across 5 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionMar 2010
Study CompletionApr 2012
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartJan 1, 2008
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.4 years ago
Interventions
saracatinibdrug
Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.